LivingGLP1
Study S001800

Feasibility Study of GLP-1 Analogues for the Optimization of Outcomes in High BMI Patients Undergoing AbLation for Atrial Fibrillation

ClinicalTrials.gov record

Registration

Registration
NCT05221229
Acronym
GOAL-AF
Study type
OBSERVATIONAL
Status
ACTIVE_NOT_RECRUITING
Enrollment
29
Start
2022-04-17
Primary completion
2025-06-30
Lead sponsor
University Hospital Birmingham
Conditions
Atrial Fibrillation; Recurrence; Overweight and Obesity; Liraglutide
Interventions
DRUG:Liraglutide plus upstream risk factors modification advice and consultation
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Adherence to Liraglutide by AF patients before and after first-time ablation [Time Frame- 13 weeks before and 52 weeks after ablation] [13 weeks before and 52 weeks after ablation]
  • Number of participants recruited over recruitment period [Time Frame-39 weeks] [39 weeks]
  • Accelerated weight loss by Liraglutide on AF patients before first-time ablation and during one year follow-up [Time Frame- 13 weeks from recruitment and 52 weeks after ablation] [13 weeks from recruitment and 52 weeks after ablation]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0015281Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol.
Win KZ, Pilot and feasibility studies
2024ProtocolPMID 38383462DOIcites ClinicalTrials.gov:NCT05221229; registry reference DERIVED:38383462
R0014537Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in Obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF)
Win KZ, Research Square
2023Randomized trialDOIcites ClinicalTrials.gov:NCT05221229